NZ728207A - Oligonucleotide-based inhibitors comprising locked nucleic acid motif - Google Patents

Oligonucleotide-based inhibitors comprising locked nucleic acid motif

Info

Publication number
NZ728207A
NZ728207A NZ728207A NZ72820713A NZ728207A NZ 728207 A NZ728207 A NZ 728207A NZ 728207 A NZ728207 A NZ 728207A NZ 72820713 A NZ72820713 A NZ 72820713A NZ 728207 A NZ728207 A NZ 728207A
Authority
NZ
New Zealand
Prior art keywords
oligonucleotides
chemically modified
oligonucleotide
locked nucleic
nucleic acid
Prior art date
Application number
NZ728207A
Inventor
Rooij Eva Van
Christina M Dalby
Rusty L Montgomery
Original Assignee
Miragen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miragen Therapeutics Inc filed Critical Miragen Therapeutics Inc
Publication of NZ728207A publication Critical patent/NZ728207A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to chemical modification motifs for oligonucleotides complementary to miR-92a. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.
NZ728207A 2012-06-21 2013-06-21 Oligonucleotide-based inhibitors comprising locked nucleic acid motif NZ728207A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662746P 2012-06-21 2012-06-21
US201361801533P 2013-03-15 2013-03-15
NZ70270613 2013-06-21

Publications (1)

Publication Number Publication Date
NZ728207A true NZ728207A (en) 2018-09-28

Family

ID=66476982

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ728207A NZ728207A (en) 2012-06-21 2013-06-21 Oligonucleotide-based inhibitors comprising locked nucleic acid motif

Country Status (1)

Country Link
NZ (1) NZ728207A (en)

Similar Documents

Publication Publication Date Title
MX355408B (en) Oligonucleotide-based inhibitors comprising locked nucleic acid motif.
HRP20210612T1 (en) Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna
MX2021015290A (en) Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes.
MX2013005875A (en) Microrna inhibitors comprising locked nucleotides.
NZ593618A (en) Gnaq targeted dsrna compositions and methods for inhibiting expression
MD20150006A2 (en) Inhibitors of the miR-15 family of micro-RNAs
EA200870402A1 (en) PHARMACEUTICAL COMPOSITION
EA201100810A1 (en) PHARMACEUTICAL COMPOSITION
WO2014154835A3 (en) Modified tgf-beta oligonucleotides
NZ592867A (en) Compositions and methods for inhibiting expression of transthyretin
MX2018013216A (en) Compositions and methods for inhibiting expression of tmprss6 gene.
MX2010004452A (en) Lipid-modified double-stranded rna having potent rna interference effect.
MX2013009191A (en) Antisense oligonucleotides.
WO2008151631A3 (en) Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
JP2014527401A5 (en)
WO2010141511A3 (en) Polynucleotides for multivalent rna interference, compositions and methods of use thereof
NZ597078A (en) CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
WO2011153323A3 (en) Compositions and methods directed to treating liver fibrosis
WO2012178033A3 (en) Serpina1 sirnas: compositions of matter and methods of treatment
WO2012177949A3 (en) Compositions and methods for inhibition of expression of protein c (proc) genes
WO2010003420A3 (en) Treatment of psoriasis and related diseases by mirna modulation
IN2014CN03921A (en)
WO2011054939A3 (en) Compositions and methods for inhibiting expression of kif10 genes
AR079649A1 (en) COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GENES IL-18
JP2018520150A5 (en)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUN 2020 BY CPA GLOBAL

Effective date: 20190509

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUN 2021 BY CPA GLOBAL

Effective date: 20200604

LAPS Patent lapsed